Longevity InTime: Autonomous AI Institute. Anti-Aging Digital Health Immortality Transhumanist AI Channel

New Model Links Brain Aging to Disrupted DNA Repair Rhythm and TyrRS Switch A theoretical model published 17 September in GeroScience ties together two hallmarks of brain aging: the buildup of DNA damage in neurons and the weakening of circadian rhythms. The authors propose the enzyme tyrosyl‑tRNA synthetase (TyrRS) as a molecular switch that coordinates both processes and explain why they falter together in aging and Alzheimer’s disease. TyrRS normally charges tyrosine onto tRNA for protein synthesis, but when free tyrosine is low — during the night or fasting — a fraction translocates to the nucleus. There it activates PARP1 to detect DNA breaks, keeps transposable‑element DNA silenced to prevent inflammation, and induces the LIN9 gene. LIN9 joins the DREAM complex, which by day represses 67 DNA‑repair genes (including BRCA1) and releases them at night for repair. The oscillation amplitude of these three activities matters more than their average level. With age, blood tyrosine rises 15–25%, narrowing the nighttime window for TyrRS action, while suprachiasmatic‑nucleus neuron loss dampens circadian rhythms. Together they lock the cascade in an intermediate state — still active but no longer swinging between peak and trough. Because the rhythm flattens, Alzheimer’s tissue shows elevated average DREAM activity, which was read as stronger repression of DNA repair. The model argues this reflects a lost oscillation, not deeper suppression. Consequently, drugs with constant release would further blunt the needed swing; a short dose timed to the sleep phase is preferable. Internal time can be measured with the HairTime test, which reads 17 clock genes from a single plucked hair. The framework aligns with Nedergaard’s findings that sleep‑driven cerebrospinal fluid flow clears amyloid and tau, explaining why lecanemab and donanemab give only modest cognitive gains. If the DNA‑repair clock is broken, 🔗 Read original →

Open LongevityBench Shows Compact AI Models Outperform Closed Giants on Aging Data Insilico Medicine and Liquid AI released the open‑access LongevityBench aging benchmark in Cell, accompanied by five compact models and the Longevity Claw tool; co‑author Vadim Gladyshev of Harvard Medical School contributed to the work. Previous aging clocks rely on a single data type, but the MMAI Gym for Science platform showed that a language model fine‑tuned on structured data can handle drug discovery, prompting the team to treat all aging measurements as text for a unified model. LongevityBench comprises 17 tasks spanning five biological data layers — clinical records, genetics, DNA methylation, blood proteins, and more — with 25,457 assignments programmatically assembled from raw measurements so answers cannot be memorized from training text. Testing 18 commercial models from OpenAI, Google, Anthropic, xAI, DeepSeek and Moonshot AI found Gemini 3.1 Pro leading but not statistically distinct from four others; after fine‑tuning five open models ranging from 0.6 – 9 billion parameters on aging data, the 9‑billion L‑Qwen3.5 secured first place with a confidence interval that did not overlap any commercial rival, while the 0.6‑billion version ranked sixth out of 26, surpassing Claude Opus 4.5, Kimi K2.5, GPT‑5.2 and Grok 4.3. A control test on published aging facts favored large universal models, indicating the compact models win through raw‑data reasoning rather than memorization; sensitivity analysis revealed that deleting the NHANES blood‑analysis block altered 47.4% of correct answers, proving reliance on real biomarkers. 🔗 Read original →

APOE4 Increases Vulnerability to Oxidative and Metabolic Stress in Fruit Flies Researchers at Texas A&M University substituted the fly’s lipid‑transport gene GLaz with either the human APOE3 or APOE4 allele. On standard food, flies carrying **APOE4 🔗 Read original →

AI Model Detects Rare Genetic Diseases Years Before Diagnosis Researchers from MyOme and the Mayo Clinic released a preprint describing a model that reads electronic health records as a chronological timeline of findings. In nearly 3 million patients the model identified signs of ten rare genetic diseases. A separate validation on 143 patients with long undiagnosed histories showed the model flagged disease before diagnosis, with a median lead time of 1.9–21.7 years. One Fabry patient, for example, endured years of limb pain, abdominal discomfort, and skin rashes before anyone connected the symptoms. On average, the diagnostic odyssey for a rare disease lasts **4–8 🔗 Read original →

FDA‑approved Friedreich’s ataxia drug found to degrade STING protein Scientists at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, showed that omaveloxolone — the FDA‑approved treatment for Friedreich’s ataxia since 2023 — binds the STING protein and triggers its cellular destruction. By preventing STING from closing, the drug exposes hydrophobic regions, lowers its melting temperature, and flags it for ubiquitination by HUWE1, leading to proteasomal degradation. At a concentration of 118 nM, cellular STING levels drop by about half; a slightly higher dose reduces STING by ≈99 %. In aged mice this depletion quelled chronic tissue inflammation that had persisted for years, without affecting body weight over two months of twice‑weekly injections. The drug also activates NRF2 via KEAP1 independently of STING, a mechanism that remains functional even when STING is genetically knocked out. Thus omaveloxolone operates through two distinct pathways: STING degradation drives the primary anti‑inflammatory effect, while NRF2 activation contributes additional cellular protection. The study was published in Nature Communications, 17 September 2026. Prior to this work, omaveloxolone’s only known target was KEAP1/NRF2, and no approved drug had directly acted on STING — experimental inhibitors such as H‑151 only blocked signaling without degrading the protein. Because omaveloxolone has already undergone clinical trials and accumulated over three years of safety data in Friedreich’s ataxia patients, its repurposing for age‑related inflammation could proceed rapidly to clinical testing. 🔗 Read original →

US Gerontologists Propose 12 Molecular Signals to Spot Real Anti‑Aging Drugs On 17 September Stephen Osted, Richard Miller and Matt Kaberlein published their analysis in Frontiers in Science. They reviewed data from the federal Interventions Testing Program (ITP), which Miller helps lead, to identify common molecular shifts in mouse models that already show slowed aging. Proving that a compound slows aging in mice currently costs $100–300 000 and takes 3–4 years; ITP can test only a small fraction of candidates, and roughly 15 % of those tested extend lifespan. The team sought a filter — a set of parameters that deviate from the norm in as many of these models as possible, regardless of the direction of change. This effort yielded 12 molecular signals that serve as a “speedometer” for aging, unlike epigenetic clocks, which act as an odometer requiring years‑spaced measurements. The signals include increased hippocampal BDNF and doublecortin, both neuroprotective and pro‑neurogenic. Of the twelve, only irisin and GPLD1 are presently measurable in blood; the rest require tissue from liver, fat, brain or muscle. A computational model built by Miller on 1051 plasma features from ITP mice correctly predicted lifespan gains for five hidden interventions. The strongest ITP result is the rapamycin + acarbose combination: it raised median lifespan by 29 % in males and 22 % in females, while rapamycin alone gave 23 % (males) and 26 % (females). Looking ahead, the authors propose validation in dogs — the Dog Aging Project already tracks >50 000 pets testing rapamycin — followed by repeat blood sampling in humans aged 55–60 at ten‑year intervals to find circulating predictors of future change. Kaberlein stresses that the main hurdle in translating aging biology to better health is knowing whether an intervention truly alters aging speed; practical biomarkers would answer this without waiting years for lifespan effects. Osted notes that many mouse geroprotectors remain fully effective when started in late adulthood, suggesting similar therapies could benefit middle‑aged people. The authors argue that the traditional “hallmarks of aging” list is a subjective construct that funnels funding toward convenient topics, and they view cellular senescence as overstated — long‑telomere mice and dogs show aging indistinguishable from short‑telomere humans. They label the field’s reluctance “gerontophobia,” a fear of studying aging slowing rather than treating its diseases. Their calculations show that eliminating all cancers after age 50 would raise human median lifespan only 2–3 %, an order of magnitude less than the lifespan boost seen in mice from rapamycin + acarbose. 🔗 Read original →

Jennifer Doudna’s Lab Discovers VIPR, a Viral Ancestor of CRISPR Jennifer Doudna’s lab at the University of California, Berkeley announced the discovery of VIPR – a family of viral proteins that are likely evolutionary precursors of CRISPR‑Cas. The findings appeared in two papers published Science on 17 September 2026. VIPR 🔗 Read original →

Sex‑Specific Organ Aging Clocks Show Divergent Alzheimer’s Risk A team at Columbia University, which has been building organ‑specific biological age models since 2023, retrained all 38 of those clocks separately for men and women on September 16 instead of using a mixed sample. The sex‑specific models proved more accurate than the combined versions and showed less over‑fitting. A genome‑wide scan of the 38 models linked them to 359 DNA loci, many of which were active in only one sex; liver and metabolism pathways were more heritable in women, while immunity and skin showed stronger genetic effects in men. Brain‑age clocks also relied on different blood proteins — SLITRK1 for women and a set of eight other proteins for men. In the ADNI cohort of people at risk for Alzheimer’s, each standard‑deviation increase in brain‑age raised the odds of moving from mild cognitive impairment to disease by 74% for men and 125% for women. The same pattern appeared in data from the solanezumab antibody trial: accelerated brain‑age predicted memory loss over 240 weeks in both sexes, whereas slower brain‑age helped women retain cognition better than men. When predicting mortality, the female‑specific model tied risk to a 🔗 Read original →

Vascular protease AEP cuts NAD+ synthesis, driving systemic aging; blocking it outpaces NAD+ supplements in mice Science Advances, September 16 – Ketsyan E’s team reports that with age the C/EBPβ/AEP pathway rises in vascular endothelial cells, and protease AEP cleaves NAMPT, the key enzyme that produces NAD+. When this pathway is heightened only in the endothelium of healthy young mice, blood flow deteriorates, the blood‑brain barrier becomes leaky, and median lifespan falls—from 769 to 518 days in males and from 807 to 520 days in females, a loss of roughly one‑third. AEP cuts NAMPT at amino‑acid position 136, destroying its ability to recycle nicotinamide into NAD+. Supplying a cleavage‑resistant NAMPT restores NAD+ production better than merely increasing NAMPT levels, showing the damage stems from the cut itself. Genetic removal of AEP or treatment with the experimental inhibitor CP#11A almost fully rescues lifespan; in a stronger activation model male median life dropped to 390 days versus 804 in controls, but AEP knockout returned it to 754 days. In accelerated‑aging mice given CP#11A or NMN from 1 🔗 Read original →

Genetic risk score for Alzheimer's aligns with observed lysosomal damage in human brain University of Washington researchers combined 14 genetic variants known to act in endosomes and lysosomes into a single score that predicted diagnosis and disease severity in two independent donor cohorts. The score was evaluated in 293 donors from their own cohort and 27,399 donors from the ADSP sequencing project, with the assessment released on 11 September. In both groups it forecast postmortem‑confirmed pathology diagnosis and severity. In cortical slices, individuals with a high risk score showed more damaged endosomes in neurons and increased lysosomal aggregates in microglia, independent of disease stage. Genome‑wide studies link DNA variants to genes indirectly; early suspects include APOE, CLU, PICALM, BIN1 and SORL1, many of which function in the endosome‑lysosome system. Loss of such genes causes endosome swelling, a phenotype also seen in mild cognitive impairment and Down syndrome before amyloid plaques appear. The team hypothesized that combining risk variants would bridge statistical diagnosis to actual organelle damage; a new preprint released on 11 September tested this idea in human tissue. RNA sequencing of 150,000 single nuclei revealed that a high risk score shifts gene expression in multiple brain cell types toward DNA‑damage response pathways while suppressing protein‑maintenance and energy‑metabolism programs, with the effect reversing across disease progression. For BIN1 and CLU, gene activity flips in a manner similar to earlier reports for a CLU risk variant; comparable logic was previously demonstrated for the SORL1 gene. The study remains postmortem; future longitudinal work with biomarkers and direct gene 🔗 Read original →

APOE4 Alters Astrocyte Genes in Locus Coeruleus, Tying Neuromelanin to Alzheimer Risk Researchers at the Lieber Institute for Brain Development, Johns Hopkins University, examined the locus coeruleus in post‑mortem tissue from 33 donors who were neurologically healthy and middle‑aged. They found that carriers of the risk allele APOE4 show reduced activity of astrocyte‑support genes in this brainstem nucleus, while neuronal genes remain largely unchanged. The pigment neuromelanin, which accumulates in these noradrenergic neurons until about 50–60 years and then declines, correlates with genes involved in cellular cleanup and antioxidant defense. MRI sensitivity to neuromelanin shows that a weaker signal predicts more severe disease, and the locus coeruleus itself is a thin strand roughly 1.5 cm long—thinner than a grain of rice—where tau pathology begins decades before memory loss. Using spatial transcriptomics—a method that maps gene activity to specific locations and cell types rather than averaging tissue—the team analyzed the same 33 donors across sex, ancestry, and APOE variants (E4 vs E2). In APOE4 carriers, the diminished gene expression was confined to neighboring astrocytes; the effect was pronounced in individuals of European ancestry but minimal in those of African ancestry, where E4‑related risk is lower. Some genes decreased equally in both groups, indicating at least two mechanisms for the risk allele. A 2024 study in Nature Medicine, 2024 showed that people with two copies of APOE4 nearly all have Alzheimer biomarkers by age 65, with symptom onset predictable as precisely as in rare familial forms. In mouse hippocampus, disabling APOE4 in neurons quelled its hyperactivity, but doing so in astrocytes did not; conversely, in the human locus coeruleus the risk appears to reside in astrocyte genes. Neuromelanin is a byproduct of norepinephrine synthesis and breakdown, structurally akin 🔗 Read original →

MoleculeMind Announces QuantaMind Neural Force Field Study of PETase On September 14, MoleculeMind announced that QuantaMind had modeled the PETase enzyme reaction in a system of 17,792 atoms. The corresponding article appeared in Science Advances on September 11. The simulation included the PETase protein, a PET substrate fragment, and 4,898 water molecules. Molecular dynamics moves atoms step by step according to interatomic forces, producing a trajectory where bonds can form or break and protons can transfer to neighboring atoms. In the hybrid approach, the reacting site is treated quantum‑mechanically while the surroundings are described with a simplified force field, with the boundary chosen in advance. QuantaMind is a neural‑network force field: given atomic coordinates it predicts the energy and forces for the next step of the trajectory. The training set comprised quantum‑chemical calculations and configurations near transition states — rare atomic arrangements where one bond breaks while another forms. PETase, a bacterial enzyme that degrades PET plastic, was selected because its structures are known but the proton transfers in its mechanism remained debated. In the calculated trajectory 🔗 Read original →

Japan’s Centenarian Surge and Fertility Drop Point to Transhumanist Solution Another "record" in Japan. The number of centenarians over 100 years old has exceeded 107,000 people, while the total fertility rate has fallen to a catastrophic 1.14. The population is rapidly heading toward 87 million by 2070, of whom nearly 40% will be elderly. Prime ministers call it a "silent existential crisis," and traditional family subsidy and birth‑stimulus programs are openly and predictably fraying at the seams. The only remedy for the demographic crisis, they say, is transhumanism. First, transhumanism shifts the focus from purely palliative care to biomedical aging therapy. Japan’s problem is not longevity itself but the period of frailty that creates a massive burden on health‑care and pension systems. Introducing "healthy longevity" technologies and treatments that repair cellular damage could turn 80- and 90-year-olds from consumers of social resources into active participants in economic and social life. Second, the gap between biological limits and modern lifestyle is closed by augments and cybernetics. Exoskeletons, implants, and neural interfaces already let older people retain physical autonomy, and when these technologies aim at enhancement rather than treatment, functionally old and young people become indistinguishable. Large‑scale development of biomedical interfaces and robotics solves the labor‑shortage problem without destabilizing society through sudden migration spikes. For policymakers, promoting a transhumanist vision is the only realistic technological survival strategy. Instead of futile attempts to make youth have more children, 🔗 Read original →

Cardiac spheroids boost early survival after heart attack in mice Danish biologists from Professor Ditte Caroline Andersen’s lab at the University of Southern Denmark transplanted mice with induced heart attacks and weakened immunity with cardiomyocytes derived from stem cells — either as loose single cells or as dense spheres of 250 cells. In the first two days, 92% of mice receiving spheres survived, compared with 36% receiving single cells and 50% receiving no cells. The results were posted as a preprint on bioRxiv on 11 September. After a heart attack the heart can lose up to a billion cardiomyocytes and cannot replace them; the adult heart lacks resident stem cells. Regenerative medicine produces such cells from induced pluripotent stem cells (iPSC) and transplants them — worldwide 12 clinical trials have been registered. Single cells wash out of the injection site and die without neighbor contact, while engineered patches persist longer but integrate poorly with cardiac tissue. Spheres represent a compromise: aggregates of several hundred cells delivered through the same thin needle, with preserved intercellular contacts that aid survival during injection. To eliminate immune confounding, the authors used the new mouse line NXG B2m, which lacks B and T lymphocytes, natural killer cells, and the gene that normally displays the “self” marker for immune surveillance. The procedure itself was nearly lethal: of 49 mice, only 50% survived the first two days with the vehicle 🔗 Read original →

Tuberous sclerosis shows Alzheimer’s-like tau marker levels due to chronic mTOR activation Duke University researchers on 11 September compared plasma p‑tau217 in 63 people with tuberous sclerosis, 25 with Alzheimer’s disease, and 116 cognitively healthy controls. The marker was significantly higher than in healthy peers, began rising at a younger age, and was statistically indistinguishable from the Alzheimer’s group. Tuberous sclerosis is a rare inherited disorder affecting 7–12 per 100,000 individuals, caused by loss‑of‑function mutations in TSC1 or TSC2, which normally restrain mTOR. Without this brake, mTOR remains hyperactive throughout life, leading to benign tumors in brain, kidneys, heart and skin, and epilepsy in most patients. Earlier Duke work found neuronal damage markers in cerebrospinal fluid and post‑mortem tau aggregates resembling Alzheimer’s pathology but lacking amyloid plaques. The link lies in chronic mTOR activation blocking autophagy, damaging synapses and allowing tau to accumulate — processes mirroring Alzheimer’s neurodegeneration. The study shifted to blood using p‑tau217, the most accurate early tau marker available. After adjusting for age and sex, p‑tau217 remained significantly higher than healthy (p < 0.0001 vs healthy; p = 0.071 vs AD) and kidney contribution was noted as modest. Independent age‑sex matching confirmed the same result. mTOR is the same pathway targeted by rapamycin longevity hypotheses; rapamycin extended lifespan in worms, yeast, flies and, in 2009, in normal mice. Human longevity trials have been inconclusive, but tuberous sclerosis offers a natural model of lifelong mTOR hyperactivity producing Alzheimer’s‑level tau pathology. Authors plan to test whether rising p‑tau217 predicts memory decline. Clinically, Aeovian is testing the selective mTORC1 inhibitor AV078 for epilepsy in this disease; if mTOR drives tau pathology, AV078 could also treat early Alzheimer‑like tau changes. 🔗 Read original →

Selective Vagus Nerve Cuff Enables Targeted Stimulation Without Battery In a pilot experiment a cuff with 14 pairs of electrodes divided the vagus nerve into sectors that control the heart and larynx. On 14 September a team from University College London demonstrated a temporary, battery‑less implant that receives power and pulse settings through NFC, like contact‑less phone payment. The device sequentially activated each cuff sector in four pigs and then, during a 30‑minute human operation, mapped 🔗 Read original →

Step‑wise AI diagnostic route improves rare disease detection A review of seven AI diagnostic systems assembled a six‑step route for rare‑disease identification. On a set of 50 test cases the route yielded the correct first diagnosis in 11 instances, whereas a single‑query GPT‑5 model got it right only 5 times. The findings were posted as a preprint on Research Square on 14 September. Across 19 evaluations of 33 738 cases the average share of correct first diagnoses was 51.2 %, with individual systems ranging from 22.0 % to 77.5 %. The authors screened 1 193 publications, read 111 full texts, and kept seven studies that together supplied those 19 accuracy measurements. The six‑phase route—extracting salient features, building and revising disease candidates, checking medical references, re‑ranking options, and recording the reasoning—was tested against a direct GPT‑5 query 🔗 Read original →

OpenAI Foundation allocates over $125 million for health‑AI data projects OpenAI Foundation — the nonprofit parent of OpenAI — launched its second scientific initiative, Public Data for Health, and awarded the first tranche of **over $125 million 🔗 Read original →

AI model using routine data improves lung cancer immunotherapy outcome prediction On 13 September, Nature Medicine published work of the I3LUNG project analyzing 2,396 patients from six clinical centers. Authors checked whether an AI prediction based on routinely collected pretreatment data could outperform standard biomarkers and change the assessment of completed cases. Immunotherapy helps the immune system attack tumors, yet in metastatic non‑small‑cell lung cancer it is hard to know who will achieve disease control and who will live longer. PD‑L1 tumor level is one guide but captures only part of the patient’s situation. The study examined how much prognostic information already exists in ordinary medical records. For the main model the authors selected nine pretreatment features: sex, smoking status, ability to perform daily activities, PD‑L1, metastasis location, and blood‑test results. In an independent patient cohort the model surpassed single biomarkers and the LIPI blood‑based index in distinguishing disease control and several survival outcomes. Adding CT scans and digital tumor‑slice images improved performance when tested on data from the same centers, but this advantage was inconsistent in external groups. The model relying only on clinical data and blood work proved more stable, and the most reliable prediction came from the pretreatment data set that physicians already have. To test usability, twenty physicians reviewed 100 case histories, first with patient data alone and then with model output and explanations of which features shifted the prediction. After the model’s suggestion, correct identification of cases where disease was kept under control rose from 0.72 to 0.87, and overall accuracy increased from 0.57 to 0.65, although false‑positive control predictions rose slightly. The next phase of I3LUNG is already underway, testing the system on more than 2,000 patients. The published paper describes its retrospective phase—analysis of accumulated clinical data and review of finished cases together with clinicians. 🔗 Read original →